Atara Biotherapeutics
Updated: April 24, 2026
Isaac Ciechanover, CEO & President
Country: USA | Funding: $566.8M (+)
Founded: 2012
Website: http://www.atarabio.com/
Atara Biotherapeutics develops allogeneic T-cell immunotherapies for the treatment of cancer, autoimmune diseases and viral diseases. The company's platform is based on allogeneic, or donor T cells that are enriched during the manufacturing process for specific receptors targeting the Epstein-Barr virus (EBV). These EBV T cells are modified with CAR to generate allogeneic CAR T-cell therapies for a broad range of antigen targets. Our molecular suite of clinically validated technologies, including the 1XX costimulatory domain, engineered to optimize physiological signaling leading to reduced exhaustion while maintaining a memory phenotype, offers a differentiated approach to addressing the significant unmet need for next-generation CAR T cells. Atara is conducting clinical trials of its candidates for the treatment of lupus nephritis and B-cell malignancies.
Founded: 2012
Website: http://www.atarabio.com/
Atara Biotherapeutics develops allogeneic T-cell immunotherapies for the treatment of cancer, autoimmune diseases and viral diseases. The company's platform is based on allogeneic, or donor T cells that are enriched during the manufacturing process for specific receptors targeting the Epstein-Barr virus (EBV). These EBV T cells are modified with CAR to generate allogeneic CAR T-cell therapies for a broad range of antigen targets. Our molecular suite of clinically validated technologies, including the 1XX costimulatory domain, engineered to optimize physiological signaling leading to reduced exhaustion while maintaining a memory phenotype, offers a differentiated approach to addressing the significant unmet need for next-generation CAR T cells. Atara is conducting clinical trials of its candidates for the treatment of lupus nephritis and B-cell malignancies.
